| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MLL2 |
| Uniprot No | O14686 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1487-1586 aa |
| 活性数据 | SKLEGMFPAYLQEAFFGKELLDLSRKALFAVGVGRPSFGLGTPKAKGDGGSERKELPTSQKGDDGPDIADEESRGLEGKADTPGPEDGGVKASPVPSDPE |
| 分子量 | 36.74 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于重组人MLL2蛋白的关键文献的简要总结(示例为虚构文献，仅供参考框架)：
1. **文献名称**：Structural Insights into the Catalytic Mechanism of Recombinant Human MLL2 Histone Methyltransferase
**作者**：Smith J, et al.
**摘要**：解析了重组人MLL2蛋白核心催化结构域的晶体结构，揭示了其依赖SAM(S-腺苷甲硫氨酸)的组蛋白H3K4三甲基化活性机制，并发现特定残基突变会显著抑制酶活性。
2. **文献名称**：Functional Characterization of Recombinant MLL2 Complex in Epigenetic Regulation
**作者**：Wang L, et al.
**摘要**：通过重组表达人MLL2蛋白及其辅因子(如WDR5和ASH2L)，证明复合物的组装是其靶向染色质并激活Hox基因表达的关键，为癌症表观遗传失调提供机制解释。
3. **文献名称**：Recombinant MLL2 Assay Development for High-Throughput Drug Screening
**作者**：Kim H, et al.
**摘要**：开发了一种基于重组人MLL2甲基转移酶活性的高通量筛选平台，用于鉴定小分子抑制剂，发现候选化合物可阻断MLL2依赖的癌细胞增殖。
**注**：以上文献为示例，实际研究中建议通过PubMed或Google Scholar以关键词“recombinant MLL2”、“MLL2 purification”、“MLL2 enzymatic activity”检索近期论文，重点关注结构生物学、酶学或疾病机制相关研究。
**Background of Recombinant Human MLL2 Protein**
The Mixed Lineage Leukemia 2 (MLL2), also known as KMT2D, is a histone methyltransferase critical for epigenetic regulation of gene expression. It belongs to the COMPASS-like family of proteins, which catalyze the methylation of histone H3 at lysine 4 (H3K4), a modification associated with active chromatin and transcriptional activation. MLL2 plays essential roles in embryonic development, cell differentiation, and tissue-specific gene regulation.
Structurally, MLL2 contains multiple functional domains, including SET domains responsible for its methyltransferase activity. Mutations or dysregulation of MLL2 are linked to developmental disorders (e.g., Kabuki syndrome) and cancers, such as leukemia and solid tumors. Its role in maintaining chromatin integrity and regulating oncogenic pathways makes it a focus of epigenetic research.
Recombinant human MLL2 protein is engineered for in vitro studies to dissect its enzymatic mechanisms, interactions with cofactors (e.g., WDR5. ASH2L), and disease-related mutations. Its production often involves heterologous expression systems (e.g., baculovirus or mammalian cells) to ensure proper post-translational modifications. Studies using recombinant MLL2 have advanced drug discovery efforts, particularly in targeting aberrant epigenetic pathways. However, challenges persist in stabilizing its large, multi-domain structure and replicating native chromatin contexts.
Overall, recombinant MLL2 serves as a vital tool for unraveling epigenetic regulation and developing therapeutics for MLL2-associated diseases.
×
